U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Buderer Drug Company Inc - 506509 - 05/01/2019
  1. Warning Letters

CLOSEOUT LETTER

Buderer Drug Company Inc MARCS-CMS 506509 —

Delivery Method:
UPS Next Day
Product:
Drugs
Recipient:
Recipient Name
James W. Buderer
Recipient Title
President
Buderer Drug Company Inc

26611 Dixie Hwy
Ste 119
Perrysburg, OH 43551-1765
United States

Issuing Office:
Center for Drug Evaluation and Research

United States

(313) 393-8100

Dear Mr. Buderer:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (CIN-16-506509-22), dated September 20, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Nicholas F. Lyons
Compliance Director
Division of Pharmaceutical Quality Operations III

Back to Top